{"id":"https://openalex.org/W4362432265","doi":"https://doi.org/10.1158/1078-0432.22479677","title":"Figure S2 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity","display_name":"Figure S2 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4362432265","doi":"https://doi.org/10.1158/1078-0432.22479677"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22479677","doi":"https://doi.org/10.1158/1078-0432.22479677","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22479677","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Figure_S2_from_Phase_I_Clinical_Trial_of_Combination_Propranolol_and_Pembrolizumab_in_Locally_Advanced_and_Metastatic_Melanoma_Safety_Tolerability_and_Preliminary_Evidence_of_Antitumor_Activity/22479677/1/files/39931181.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Figure_S2_from_Phase_I_Clinical_Trial_of_Combination_Propranolol_and_Pembrolizumab_in_Locally_Advanced_and_Metastatic_Melanoma_Safety_Tolerability_and_Preliminary_Evidence_of_Antitumor_Activity/22479677/1/files/39931181.pdf","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064151962","display_name":"Shipra Gandhi","orcid":"https://orcid.org/0000-0003-3506-0284","observed_orcids":["https://orcid.org/0000-0003-3506-0284"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shipra Gandhi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089941327","display_name":"Manu Raj Pandey","orcid":"https://orcid.org/0000-0002-5276-3806","observed_orcids":["https://orcid.org/0000-0002-5276-3806"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Manu R. Pandey","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011054139","display_name":"Kristopher M. Attwood","orcid":"https://orcid.org/0000-0002-7229-5472","observed_orcids":["https://orcid.org/0000-0002-7229-5472","https://orcid.org/0009-0003-3874-1293"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kristopher Attwood","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Wenyan Ji","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wenyan Ji","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034535391","display_name":"Agnieszka Katarzyna Witkiewicz","orcid":"https://orcid.org/0000-0003-4538-1145","observed_orcids":["https://orcid.org/0000-0003-4538-1145"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Agnieszka K. Witkiewicz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029801038","display_name":"Erik S. Knudsen","orcid":"https://orcid.org/0000-0002-5130-5969","observed_orcids":["https://orcid.org/0000-0002-5130-5969"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Erik S. Knudsen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5130-5969","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110967141","display_name":"Cheryl L. Allen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cheryl Allen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053887896","display_name":"Joseph Dennis Tario","orcid":"https://orcid.org/0009-0009-2145-6617","observed_orcids":["https://orcid.org/0009-0009-2145-6617"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joseph D. Tario","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065404552","display_name":"Paul K. Wallace","orcid":"https://orcid.org/0000-0001-7823-9917","observed_orcids":["https://orcid.org/0000-0001-7823-9917"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul K. Wallace","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109602063","display_name":"Carlos D. Cedeno","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carlos D. Cedeno","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058935510","display_name":"Maria Levis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maria Levis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078413773","display_name":"Suzanne M. Stack","orcid":"https://orcid.org/0000-0003-4256-8035","observed_orcids":["https://orcid.org/0000-0003-4256-8035"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Suzanne Stack","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4256-8035","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057402683","display_name":"Pauline Funchain","orcid":"https://orcid.org/0000-0002-7568-8626","observed_orcids":["https://orcid.org/0000-0002-7568-8626"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pauline Funchain","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018176156","display_name":"Joseph J. Drabick","orcid":"https://orcid.org/0000-0002-7630-2721","observed_orcids":["https://orcid.org/0000-0002-7630-2721"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joseph J. Drabick","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078984239","display_name":"Mark J. Bucsek","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark J. Bucsek","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049243227","display_name":"Igor J. Puzanov","orcid":"https://orcid.org/0000-0002-9803-3497","observed_orcids":["https://orcid.org/0000-0002-9803-3497"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Igor Puzanov","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071658240","display_name":"Hemn Mohammadpour","orcid":"https://orcid.org/0000-0002-0158-7283","observed_orcids":["https://orcid.org/0000-0002-0158-7283"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hemn Mohammadpour","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029344793","display_name":"Elizabeth A. Repasky","orcid":"https://orcid.org/0000-0002-9554-4152","observed_orcids":["https://orcid.org/0000-0002-9554-4152"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elizabeth A. Repasky","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5089516753","display_name":"Marc S. Ernstoff","orcid":"https://orcid.org/0000-0002-8132-7069","observed_orcids":["https://orcid.org/0000-0002-8132-7069"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marc S. Ernstoff","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.013399999588727951,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.005200000014156103,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/propranolol","display_name":"propranolol","score":0.9610000252723694},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":1.0},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.7450000047683716},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.6790000200271606},{"id":"https://openalex.org/keywords/cxcl10","display_name":"CXCL10","score":0.828000009059906},{"id":"https://openalex.org/keywords/eotaxin","display_name":"eotaxin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/tumor-necrosis-factor-beta","display_name":"lymphotoxin","score":0.9359999895095825},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.9649999737739563},{"id":"https://openalex.org/keywords/myeloid-derived-suppressor-cells","display_name":"myeloid-derived suppressor cells","score":0.9340000152587891},{"id":"https://openalex.org/keywords/pmn-mdscs","display_name":"polymorphonuclear myeloid-derived suppressor cells","score":0.9010000228881836},{"id":"https://openalex.org/keywords/regulatory-t-cells","display_name":"regulatory T cells","score":0.9940000176429749},{"id":"https://openalex.org/keywords/il-12p70","display_name":"IL-12p70","score":0.9649999737739563},{"id":"https://openalex.org/keywords/chemokines","display_name":"chemokines","score":0.828000009059906},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.597000002861023},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.671999990940094}],"concepts":[{"id":"https://openalex.org/C2778151854","wikidata":"https://www.wikidata.org/wiki/Q423364","display_name":"Propranolol","level":2,"score":0.7114874720573425},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.7070636749267578},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5403234958648682},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4988720417022705},{"id":"https://openalex.org/C13373296","wikidata":"https://www.wikidata.org/wiki/Q421866","display_name":"Chemokine","level":3,"score":0.4964960217475891},{"id":"https://openalex.org/C3017910909","wikidata":"https://www.wikidata.org/wiki/Q618363","display_name":"Peripheral blood","level":2,"score":0.48824694752693176},{"id":"https://openalex.org/C2777716647","wikidata":"https://www.wikidata.org/wiki/Q5381961","display_name":"Eotaxin","level":4,"score":0.4829520583152771},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.47505638003349304},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.47427234053611755},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.42935624718666077},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3486860692501068},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3279454708099365},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3046318590641022},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.2044563591480255},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.19161412119865417},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.1874053180217743},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.18650579452514648},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.16864946484565735},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.12357360124588013}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.22479677","doi":"https://doi.org/10.1158/1078-0432.22479677","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22479677","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Figure_S2_from_Phase_I_Clinical_Trial_of_Combination_Propranolol_and_Pembrolizumab_in_Locally_Advanced_and_Metastatic_Melanoma_Safety_Tolerability_and_Preliminary_Evidence_of_Antitumor_Activity/22479677/1/files/39931181.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22479677","doi":"https://doi.org/10.1158/1078-0432.22479677","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22479677","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Figure_S2_from_Phase_I_Clinical_Trial_of_Combination_Propranolol_and_Pembrolizumab_in_Locally_Advanced_and_Metastatic_Melanoma_Safety_Tolerability_and_Preliminary_Evidence_of_Antitumor_Activity/22479677/1/files/39931181.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4362432265.pdf","grobid_xml":"https://content.openalex.org/works/W4362432265.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4362415019","https://openalex.org/W4232093254","https://openalex.org/W4362411452","https://openalex.org/W4361939064","https://openalex.org/W4361939052","https://openalex.org/W4362411008","https://openalex.org/W4361939089","https://openalex.org/W4361953658","https://openalex.org/W3095647733","https://openalex.org/W4361939075"],"abstract_inverted_index":{"Biomarker":[0],"changes":[1,36],"over":[2],"time.":[3],"A,":[4],"Variations":[5],"in":[6,12,16,37,85],"chemokines":[7],"IP-10,":[8],"eotaxin":[9],"and":[10,47,65],"TNF-\u03b2":[11],"pg/ml.":[13],"B,":[14],"Variation":[15],"CD8+T-cells,":[17],"m-MDSC,":[18],"PMN-MDSC,":[19],"regulatory":[20],"T-cells":[21],"(Tregs)":[22],"expressed":[23],"as":[24],"percentage":[25],"of":[26,31],"total":[27],"CD45+":[28],"cells,":[29],"ratio":[30],"CD8+/":[32],"PMN-MDSC.":[33],"C,":[34],"Relative":[35],"peripheral":[38],"blood":[39],"cells":[40],"(PMN-MDSC,":[41],"CD8+":[42,44],"T-cell,":[43],"T":[45],"cells/T-reg)":[46],"IL-12p70.":[48],"Dose":[49],"level":[50,58,67],"1":[51],"is":[52,60,69],"propranolol":[53,61,70],"10":[54],"mg":[55,63,72],"BID,":[56],"dose":[57,66,87],"2":[59],"20":[62],"BID":[64],"3":[68],"30":[71],"BID.":[73],"Asterix":[74],"show":[75],"significant":[76],"values":[77],"at":[78],"different":[79,86],"time":[80],"points":[81],"compared":[82],"to":[83],"baseline":[84],"levels.":[88]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2023-04-05T00:00:00"}